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Introduction
The coronavirus disease 2019 (COVID-19) pandemic is an 
ongoing global issue [1,2]. In South Korea, the first COVID-19 
–positive patient was diagnosed on January 20, 2020 [3]. Since 
then, COVID-19 has caused serious health concerns in the 
treatment of cancer patients [4-7]. Quarantine protocols have 
been issued by the South Korean Government, including the 
Central Disaster and Safety Countermeasures Headquarters 
[3].
The guideline presented here was developed to help onco- 
logists manage cancer patients who have a high mortal-
ity rate. Other countries have developed COVID-19–specific 
cancer guidelines [7-9]. The difference in situation and man-
agement in South Korea prompted the development of guide-
lines specifically for South Korean oncologists. We hope that 
these guidelines will provide clinical guidance to cancer care 
during the ongoing COVID-19 pandemic. 
Method
 
The guideline was first written in Korean in April 2020 by 
clinical experts who were members of the Korean Cancer 
Association and the National Cancer Center and include gen-
eral guidelines for cancer care and specific recommendations 
for surgery, chemotherapy, radiotherapy, pediatric oncology, 
cancer screening, and clinical trials. Many of the information 
provided here were developed from experts’ opinions and 
experience during the time when COVID-19 pandemic hit 
Korea in March. The guideline was then translated to Eng-
lish so that the clinicians around the world may have access 
to this guideline. All authors unanimously agree to the rec-
ommendations as outlined in the guideline. In general, the 
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guideline for screening, treatment and follow-up for cancer 
care primarily depends on two factors: (1) the shortages in 
medical devices or healthcare workers, and (2) whether the 
patient is positive for COVID-19 (Fig. 1).   
General Guidelines
1. Prevention
Guidelines for cancer patients may be modified during 
massive regional or national COVID-19 outbreaks. Clinic-
ians should discuss the benefits and risks of cancer treat-
ment with patients before making treatment decisions. Both 
healthcare workers and patients should wash their hands 
and wear masks during face-to-face communication. The 
clinic and facilities treating patients must be large, open, and 
well-ventilated. The 2-m social distancing rule should be 
applied. Patients should be educated about the symptoms of 
COVID-19. 
2. Treatment
COVID-19–positive cancer patients should be treated in 
the same manner as COVID-19–positive patients without 
cancer. Stop all cancer treatments such as elective surgery, 
chemotherapy, and radiotherapy if a cancer patient is diag-
nosed with COVID-19. Patients should be admitted to hos-
pital since they are at a high risk of severe disease. Cancer 
treatment may resume once they recover from COVID-19. 
Patients who have completed their cancer treatment or are 
under surveillance for recurrence should not postpone rou-
tine tests or hospital visits. Postponing follow-up tests and 
hospital visits should only occur if there are shortages of 
medical devices or healthcare workers. 
3. Facility
Healthcare facilities should establish a diagnostic labora-
tory in which cancer patients suspected with COVID-19 can 
be tested rapidly. Establish a network for patient referral and 
swiftly refer to another hospital when necessary. Prevent 
delays in patient treatment if there is a COVID-19 outbreak 
in healthcare facilities. Clinicians are recommended to com-
municate via telemedicine. Options include telephone-only 
consultation, virtual check-in, and e-visits. 
Separate triage stations for COVID-19 screening should 
be established for both outpatient clinics and emergency 
departments. Patients should be screened if they have the 
following conditions: (1) symptoms related to COVID-19, (2) 
a history of recent overseas travel within 14 days, or (3) con-
tact with a COVID-19 patient. Once a patient is tested nega-
tive for COVID-19 disease, the patient should be referred to 
the outpatient clinic or admit to the ward, as appropriate. 
Surgery
Surgery should not be postponed due to the potential risk 
of cancer progression. At the discretion of doctors, surgery 
may be delayed, but the decisions must be based on an indi-
vidual basis. Emergency operations should never be delayed. 
Prior to surgery, factors such as the center’s infrastructure 
to treat COVID-19–positive patients, the status of healthcare 
workers, and availability of the intensive care units and gen-
eral wards should be considered. Prior to elective surgery, all 
patients should be screened for COVID-19. 
Clinicians should wear personal protective equipment 
(PPE) during surgery for febrile patients waiting for COV-
ID-19 test results [10]. The least possible number of staff 
should be allowed to assist during surgery. The patient shou-
ld recover in the operation room after surgery. While await-
ing the COVID-19 test results, the recovered patient should 
be send to an isolation ward via a safe route. The patient 
should be sent to the general ward only after testing negative 
Fig. 1.  Basic algorithm for screening, treatment and follow-up during coronavirus disease 2019 (COVID-19). a)Indications for COVID-19 
screening includes one of the following: (1) symptoms related to COVID-19, (2) history of recent overseas travel within 14 days, contact 
with a COVID-19 patient, b)Delay: Refer to Table 2 for summary of recommendations for cancer screening.
Shortage in medical devices
or healthcare workers










Refer to other hospitals OR
Delay screening, treatment and follow-up
Jii Bum Lee, Cancer Care During COVID-19 in Korea
VOLUME 53 NUMBER 2 APRiL 2021     325
for COVID-19.
The following are necessary equipment for healthcare 
workers, including surgeons, anesthesiologists, and nurses: 
PPE including double gloves, N95 face mask, goggles, sur-
gical cap, surgical gown, and shoe covers. For COVID-19 
patients or suspected COVID-19 patients, medical staff 
should wear level D PPE, powered with an air-purifying res-
pirator (PAPR). Alternatives to surgery, such as cancer drugs 
and radiation treatment, should be considered in the case of 
large-scale COVID-19 outbreaks that result in a shortage of 
healthcare workers.
Chemotherapy
Chemotherapy should be administered on an individual 
basis since COVID-19 outbreaks and medical resources can 
vary regionally. During epidemic breakout of COVID-19, 
patients with a low risk of COVID-19 should continue rou-
tine chemotherapy. During pandemic COVID-19 era, where 
there is a high risk for COVID-19 leading to a shortage of 
medical resources and healthcare workers, patients are 
advised to postpones admission to wards. They are encour-
aged to be diagnosed and treated in outpatient clinics to 
prevent COVID-19. Outpatient clinics may be rescheduled. 
Patients should minimize hospital visits by communicating 
via telemedicine, preferably by phone or virtually, rather 
than having face-to-face interaction. 
Clinicians are advised to implement treatment strategies 
with fewer hospital visits. Clinicians may change the route 
of chemotherapy (hormonal treatment) from intravenous to 
oral and treat in outpatient clinics. If possible, use chemo-
therapy with longer treatment cycles to avoid frequent hos-
pital visits. 
Cancer patients receiving adjuvant chemotherapy should 
not delay treatment except during a shortage of medical 
resources, in which case the patients should be referred to 
other hospitals. The clinicians should discuss the benefits 
and risks of omitting or delaying treatment, including the 
possibility of recurrence to the patients.
Patients with advanced or recurrent solid tumors requir-
ing palliative chemotherapy should continue treatment. 
During a shortage of medical resources, chemotherapy may 
be postponed only if the primary physician believes that the 
disease progression is slow and the cancer-related symp-
toms are minimal. However, palliative chemotherapy should 
not be delayed if the patient is experiencing symptoms or 
rapid progression. Implement ways to minimize emergency 
department visits related to chemotherapeutic side effects. 
In patients with febrile neutropenia after chemotherapy, 
clinicians should exercise caution because it is difficult to dis-
tinguish COVID-19 from other viral infections. Clinicians are 
advised to use granulocyte colony-stimulating factor. Dose 
reduction or delay future chemotherapy should be consid-
ered in the next treatment cycle. COVID-19 must be screened 
for asymptomatic patients who need admission to ward. 
However, it is not mandatory for asymptomatic patients 
receiving chemotherapy in the outpatient clinic. 
Radiotherapy 
Generally, patients with de novo tumors requiring radio-
therapy should not mandatorily delay radiation treatment. 
However, radiotherapy may be withheld and substituted 
with other treatment if the patient is asymptomatic or in poor 
general condition. During a shortage of medical resources, 
radiation may be delayed at the discretion of the radiation 
oncologist. With the exception of emergency and life-threat-
ening conditions such as spinal cord compression, cauda 
equina syndrome, increased intracranial pressure, superior 
vena cava syndrome, obstruction of airways, hemoptysis, 
and tumor bleeding, all other elective radiotherapy may be 
delayed. For hypofractionated radiotherapy, the dosage of 
radiation maybe increased and the frequency of treatment 
decreased.
 For patients who are tested positive for COVID-19, radia-
tion treatment may be withheld unless they require the im-
mediate interventions due to emergency and life-threating 
conditions. Treatment may be resumed once the patient 
recovers from COVID-19. Radiologists may consider increas-
ing the total dose of radiation after the unexpected “treat-
Table 1.  General guidelines for cancer screening 
Criteria Recommendations
For patients Patients are instructed to take off their face mask only when necessary (ex: esophagogastroduodenoscopy). 
   Otherwise, patients must wear their face mask at all times. 
 Apply the 2-m social distancing rule in waiting areas.
 The outpatient clinic should be limited to one patient at a time during a procedure.
For healthcare workers Wash hands before and after contact with the patient and surrounding areas. 
 If possible, consider communicating results over the phone.
Cancer Res Treat. 2021;53(2):323-329
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ment holiday.”
After completion of radiotherapy, follow-up visits may be 
delayed or minimized at the discretion of radiation oncolo-
gists. In patients with stable condition who do not have any 
side effects from radiation treatment, less stringent follow-up 
visits are recommended with a follow-up of 3-month period.
Pediatric Oncology
Currently, there are no guidelines for treatment of pediat-
ric COVID-19 patients. Generally, pediatric cancer patients 
higher risk for COVID-19 complications than healthy adults 
[11]. In infants, children, and adolescents, the symptoms of 
COVID-19 appear as respiratory symptoms, such as fever, 
cough, and dyspnea, and non-respiratory symptoms, such 
as vomiting and diarrhea. 
Chemotherapy in pediatric oncology patients should not 
be delayed. Patients who received chemotherapy or surgery 
within a month of COVID-19 are likely to develop more 
severe infection. Therefore, patients with symptoms such 
as fever and cough should be treated promptly. Minimize 
hospital visits by delaying outpatient clinic appointments or 
substituting with telephone-only visits for patients who have 
completed chemotherapy. Maintain regular follow-up visits. 
Consider switching from intravenous drugs to oral drugs, if 
possible. 
Although there are no standardized guidelines for pediat-
ric patients preparing for stem cell transplantation, the Euro-
pean Society for Blood and Marrow Transplantation guide-
Table 2.  Summary of recommendations for cancer screening
Cancer Gastric cancer  Colon cancer HCC Cervical cancer Lung cancer Breast cancer
Diagnostic modality Endoscopy Endoscopy USG, AFP Pap smear LDCT Mammography
Risk stratification - - Prioritize  - - -
     screening 
     for high risk 
     patientsa) 
Preventative measures  PPEb) PPEb) - - - -
  for healthcare workers  
Sanitation protocol Requiredc) Requiredc) - - - -
For COVID-19–positive  Enhanced PPE  Enhanced PPE - - - -
  asymptomatic patients   (level D, powered   (level D, powered
   with an PAPR)   with an PAPR) 
AFP, α-fetoprotein; COVID-19, coronavirus disease 2019; HCC, hepatocellular carcinoma; LDCT, low-dose computed tomography; PAPR, 
air-purifying respirator; PPE, personal protective equipment; USG, ultrasonography. a)High risk patients include patients with elevated AFP 
levels, liver cirrhosis, or chronic hepatitis B, b)PPE includes gloves, face mask, plastic barrier gown and goggles/face shields. Enhanced PPE 
includes level D, powered with an PAPR, c)Refer to Table 3 for sanitation protocol.
Table 3.  Specific recommendations for screening with endoscopy
Criteria Recommendations
Sanitization protocol Follow the protocols as outlined by the Korean Society of Gastrointestinal Endoscopy [13].
 Use disinfectant wipes to clean the bed after each endoscopic procedure.
 Disinfectant containing bleach (1:40, sodium hypochlorite 25 mL: water 1 L, 1,000 ppm) 
   must be used to clean the floor.
 Use disinfectant wipes such as Rely+On Virkon Micro Tissue or ED wipes. 
 For a suspected COVID-19 patient, disinfect all areas that had contact with the patient including the 
   equipment and floors. Rub with disinfectant at least three times.
Facility cleaning Use ceiling-mounted air conditioners with fan coils to ventilate.
 Place the air vents in the area for disinfecting and cleaning the endoscopes.
 Open the doors and windows in the waiting area twice a day, in the morning and afternoon.
 Use checklists for cleaning and clean facility twice a day, in the morning and afternoon.
COVID-19, coronavirus disease 2019.
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Table 4.  Summary of cancer care during COVID-19
Criteria Recommendations
General guidelines Both healthcare workers and patients should wash their hands and wear masks during face-to-face 
   communication.
 The 2-m social distancing rule should be applied.
 COVID-19–positive cancer patients should be treated in the same manner as COVID-19–positive patients 
   without cancer.
 Stop all cancer treatments such as elective surgery, chemotherapy, and radiotherapy if a cancer patient 
   is diagnosed with COVID-19.
 Postponing follow-up tests and hospital visits should only occur if there are shortages of medical devices or 
   healthcare workers.
 Separate triage stations for COVID-19 screening should be established for both outpatient clinics and 
   emergency departments.
 Patients should be screened if they have the following conditions: (1) symptoms related to COVID-19, 
   (2) a history of recent overseas travel, or (3) contact with a COVID-19 patient.
Surgery Surgery should not be postponed due to the potential risk of cancer progression.
 Prior to elective surgery, all patients should be screened for COVID-19.
 Clinicians should wear personal protective equipment (PPE) which includes double gloves, N95 face mask, 
   goggles, surgical cap, surgical gown, and shoe covers.
 For COVID-19 patients or suspected COVID-19 patients, medical staff should wear Level D PPE, 
   powered with an air-purifying respirator (PAPR).
 Alternatives to surgery, such as cancer drugs and radiation treatment, should be considered in the case of 
   large-scale COVID-19 outbreaks that result in a shortage of healthcare workers.
Chemotherapy Clinicians are advised to implement treatment strategies with fewer hospital visits.
 For patients treated in adjuvant or palliative setting, we advise that the treatments should not be delayed.
 Use granulocyte colony-stimulating factor in patients with febrile neutropenia after chemotherapy, 
   and consider dose reduction or delay in subsequent chemotherapy.
 COVID-19 must be screened for asymptomatic patients who need admission to ward.
Radiotherapy Patients with de novo tumors requiring radiotherapy should not delay radiation treatment.
 With the exception of emergency and life-threatening conditions such as spinal cord compression, 
   cauda equina syndrome, increased intracranial pressure, superior vena cava syndrome, 
   obstruction of airways, hemoptysis, and tumor bleeding, all other elective radiotherapy may 
   be delayed during a shortage of medical resources.
 During a shortage in medical resources, the dosage of radiation maybe increased and the frequency of 
   treatment for hypofractionated radiotherapy. Follow-up visits may be delayed after 
   a multi-disciplinary approach.
Pediatric oncology Pediatric cancer patients are immunocompromised, more susceptible to viral infections including 
   COVID-19, and have a higher COVID-19 mortality rate.
 Both donor and recipient are screened for COVID-19 should be screened prior to stem cell transplantation.
Cancer screening Cancer screening should not be delayed in healthy patients.
 Asymptomatic patients who are unlikely to have COVID-19 may proceed with cancer screening without 
   COVID-19 results.
 With the exception of screening with endoscopy, all cancer screening should be delayed in 
   COVID-19–positive patients until they are tested negative.
 Healthcare workers must use PPE during the procedure and follow sanitation protocols during 
   endoscopic procedures.
Clinical trial The trial sponsors and clinical trial centers, including the Institutional Review Board (IRB) members and 
   the principal investigators, should adhere to the protocol outlined by the Ministry of Food and Drug Safety.
 Ensure the safety of patients and staff by taking precautionary measures during the storage, shipment, 
   and delivery of biological samples.
COVID-19, coronavirus disease 2019.
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lines recommend that both donor and recipient are screened 
for COVID-19 [12]. Prior to stem cell transplantation, opti-
mize blood storage to prevent a lack of blood supply during 
transfusions. 
All treatments, including non-elective surgery, chemother-
apy, and radiotherapy should be withheld in COVID-19–
positive pediatric patients, and COVID-19 should be treated 
immediately. Admit the patients to hospitals since they are at 
a high risk of serious disease. Patients should be rigorously 
monitored even after treatment, since they are immunocom-
promised and can spread COVID-19 even if they are asymp-
tomatic. Cancer-related treatments may resume once they 
recover from COVID-19.
Cancer Screening
The guidelines for cancer screening are outlined in Table 1. 
In general, cancer screening should not be delayed in healthy 
patients. Asymptomatic patients who are unlikely to have 
COVID-19 may proceed with cancer screening without 
COVID-19 results. Screening methods such as Pap smear, 
mammography, and low-dose computed tomography for 
cervical cancer, breast cancer, and lung cancer respectively, 
may be postponed if there is a shortage of medical resources. 
With the exception of screening with endoscopy, all cancer 
screening should be delayed in COVID-19–positive patients 
until they are tested negative (Table 2). 
For gastric and colon cancer screening, check if the pati-
ents have fever or respiratory symptoms and screen for 
COVID-19. Healthcare workers must use PPE during the 
procedure and follow sanitation protocols during endoscop-
ic procedures. For COVID-19–positive asymptomatic pati-
ents, proceed with the endoscopy in a setting of enhanced 
PPE (level D, powered with an PAPR). Follow the proto-
cols for sanitation and facility cleaning as recommended in 
Table 3. For patients screening for hepatocellular carcinoma, 
risk factors should be stratified. Patients with low risk may 
postpone screening. During a shortage of medical resources, 
prioritize screening patients who have elevated α-fetoprotein 
levels, liver cirrhosis, and chronic hepatitis B. Encourage 
patients who are current smokers and are at high risk of both 
lung cancer and COVID-19, to stop smoking.
Clinical Trials 
Patient safety is the foremost priority during clinical tri-
als. The principal investigator, sub-investigator, and clinical 
research coordinator must follow the general guidelines for 
COVID-19 prevention. The trial sponsors and clinical trial 
centers, including the Institutional Review Board (IRB) mem-
bers and the principal investigators, should adhere to the 
protocol as outlined by the Ministry of Food and Drug. The 
investigators should consult sponsors about the possibility 
of protocol deviations during the COVID-19 pandemic. Cli-
nicians should enroll and treat the subject as outlined in the 
clinical trial protocol. Assess and ensure the safe shipment of 
investigational products. Ensure the safety of patients and 
staff by taking precautionary measures during the storage, 
shipment, and delivery of biological samples. One method is 
to sanitize the external packages received.
Conclusion
The summary of general guidelines, surgery, chemother-
apy, radiotherapy, pediatric oncology, cancer screening, and 
clinical trial for cancer patients during the COVID-19 pan-
demic is outlined in Table 4. Lastly, individualized treatment 
strategies and discretion of clinicians are needed to adjust 
to the challenges faced with maintaining cancer care in the 
COVID-19 era.
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